Mesoblast (ASX: MSB) Falls 7% Despite Record US$30.3M Ryoncil Quarter- Is This the Dip to Buy?

Mesoblast Shares Fall Despite Record Sales

Mesoblast (ASX: MSB) shares fell around 7% on Tuesday, trading near A$1.98, after the company reported its best-ever quarterly Ryoncil sales. Net sales for the quarter ended March 31, 2026, came in at US$30.3 million, with strong February and March demand making up for a slow January. On the surface, that looks like great news. So why are investors selling? The answer tells you a lot about where Mesoblast sits right now as an investment.

What are the Best ASX Healthcare Stocks to invest in right now?

Check our buy/sell tips

Ryoncil’s Commercial Ramp Is the Real Story

Ryoncil is Mesoblast’s stem cell therapy approved to treat a severe immune condition in children called steroid-refractory acute graft-versus-host disease. It received FDA approval in December 2024 and only started generating meaningful revenue in 2025. The fact that it is already delivering over US$30 million per quarter in its first full year of launch is genuinely impressive.

To put that in context, total Ryoncil revenue across the first year of launch is now approaching US$100 million. Management has guided for US$110 to US$120 million in net Ryoncil revenue for the full financial year. We believe this trajectory is ahead of what most investors expected when the product launched, and it signals that hospital adoption in the US is building real momentum.

What makes this even more exciting is what comes next. Mesoblast is planning a clinical trial to expand Ryoncil’s approved use to adult patients with the same condition. That adult market is roughly three times larger than the current paediatric one. If that trial succeeds, the revenue ceiling for Ryoncil rises significantly.

Why the Market Isn’t Convinced Yet

Here is the catch. Strong sales do not yet equal profits. Mesoblast is still losing money each quarter because the costs of commercialising Ryoncil, running clinical trials, and building out manufacturing are significant. The company is spending around US$16 million in cash per quarter on operations, which means it needs Ryoncil to keep growing before it can reach breakeven.

Adding to the pressure this week is a new share issuance announcement. Any time Mesoblast issues new shares, it dilutes existing holders, and the market tends to react negatively in the short term, regardless of how the underlying business is tracking. This pattern has frustrated long-term shareholders more than once.

The Investor’s Takeaway

Mesoblast is not a broken story. The company holds US$130 million in cash and recently secured a US$125 million credit facility at a competitive interest rate, giving it real financial flexibility. The Ryoncil numbers are moving in the right direction.

However, the road to profitability still has some distance to travel. For growth investors comfortable with biotech risk, the current dip could offer an attractive entry point if you believe Ryoncil’s ramp continues. For more conservative investors, waiting to see consistent progress towards breakeven before committing capital is a reasonable approach.

In our view, the Ryoncil story is intact. But patience remains essential here.